Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Toxicity Testing in Animals01:23

Toxicity Testing in Animals

124
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
124
Genetic Screens02:46

Genetic Screens

5.9K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
5.9K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

2.1K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.1K
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.4K
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

17.6K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
17.6K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

502
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
502

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The "completely randomised" and the "randomised block" are the only experimental designs suitable for widespread use in pre-clinical research.

Scientific reports·2020
Same author

The design and statistical analysis of animal experiments: introduction to this issue.

ILAR journal·2014
Same author

Evidence should trump intuition by preferring inbred strains to outbred stocks in preclinical research.

ILAR journal·2014
Same author

Randomized block experimental designs can increase the power and reproducibility of laboratory animal experiments.

ILAR journal·2014
Same author

The extended statistical analysis of toxicity tests using standardised effect sizes (SESs): a comparison of nine published papers.

PloS one·2014
Same author

Extending the statistical analysis and graphical presentation of toxicity test results using standardized effect sizes.

Toxicologic pathology·2014

Related Experiment Video

Updated: Mar 21, 2026

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

13.2K

Genetically Defined Strains in Drug Development and Toxicity Testing.

Michael F W Festing1

  • 1c/o Medical Research Council Toxicology Unit, University of Leicester, Leicester, UK. michaelfesting@aol.com.

Methods in Molecular Biology (Clifton, N.J.)
|May 7, 2016
PubMed
Summary

Pre-clinical animal studies often lack repeatability, wasting billions annually. Using genetically defined rodent strains instead of undefined ones could improve test reliability and reduce wasted research funding.

Keywords:
Drug developmentExperimental designFactorial experimental designsInbred strainsPreclinical developmentSignal/noise ratioStatistical analysisStatisticsToxicity testing

More Related Videos

The Lambda Select cII Mutation Detection System
07:08

The Lambda Select cII Mutation Detection System

Published on: April 26, 2018

8.4K
Protocol for the Differentiation of Human Induced Pluripotent Stem Cells into Mixed Cultures of Neurons and Glia for Neurotoxicity Testing
09:02

Protocol for the Differentiation of Human Induced Pluripotent Stem Cells into Mixed Cultures of Neurons and Glia for Neurotoxicity Testing

Published on: June 9, 2017

24.6K

Related Experiment Videos

Last Updated: Mar 21, 2026

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

13.2K
The Lambda Select cII Mutation Detection System
07:08

The Lambda Select cII Mutation Detection System

Published on: April 26, 2018

8.4K
Protocol for the Differentiation of Human Induced Pluripotent Stem Cells into Mixed Cultures of Neurons and Glia for Neurotoxicity Testing
09:02

Protocol for the Differentiation of Human Induced Pluripotent Stem Cells into Mixed Cultures of Neurons and Glia for Neurotoxicity Testing

Published on: June 9, 2017

24.6K

Area of Science:

  • Toxicology
  • Laboratory Animal Science
  • Drug Development

Background:

  • Pre-clinical experiments using laboratory animals face significant challenges with poor quality and lack of repeatability.
  • This leads to substantial financial waste, estimated at $28 billion annually in the USA alone.
  • Traditional toxicity tests (e.g., 28-day and 90-day repeat-dose studies in rodents) have not been formally evaluated for their repeatability and power to detect adverse effects.

Purpose of the Study:

  • To address the poor quality and lack of repeatability in pre-clinical animal toxicity testing.
  • To propose an alternative strategy for toxicity testing that enhances reliability and data quality.
  • To advocate for the use of genetically defined rodent strains in toxicity studies.

Main Methods:

  • Critically evaluating current repeat-dose toxicity test guidelines (OECD TG 407 and 408).
  • Highlighting the limitations of using genetically undefined rodent stocks (e.g., "albino" rats or mice).
  • Proposing the use of multiple, genetically defined inbred rodent strains instead of undefined outbred stocks.

Main Results:

  • Genetically undefined rodent stocks introduce unknown and uncontrolled genetic variation, contributing to inter-individual and strain variability.
  • Inbred strains offer greater stability and more repeatable data compared to outbred stocks.
  • The phenotypic uniformity of inbred strains is expected to result in more powerful and repeatable toxicity tests.

Conclusions:

  • The current reliance on genetically undefined animals in toxicity testing compromises data quality and repeatability.
  • Utilizing small numbers of genetically defined rodent strains offers a more robust and reliable approach to safety assessment.
  • Regulatory bodies and funding organizations should support research into this alternative strategy to improve pre-clinical research efficiency and reduce waste.